Clinical Trial Update: Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study [Phase 2]

View source ↗

Summary

Phase 2 RELIEVE-01 trial from Fudan University is evaluating organ preservation with tislelizumab plus total neoadjuvant therapy in patients with low rectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: RECTAL NEOPLASMS, Rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING